225Ac-PSMA-617 Hematologic Toxicity in mCRPC Linked to "Triple-Hit" Mechanism; Risk Stratification Proposed
Tumor microenvironment-mediated hematologic toxicity of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer: mechanisms, risk stratification, and clinical management.
Abstract
225Ac-PSMA-617's hematologic toxicity in mCRPC is attributed to a "triple-hit" mechanism, leading to a new clinical risk stratification framework.